The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Characteristics and outcomes of patients with AML and FLT3-TKD mutations
Sankalp Arora, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the characteristics and outcomes of patients with acute myeloid leukemia (AML) and FLT3-TKD mutations. Dr Arora notes that NPM1 mutations often co-occur with FLT3-TKD, which affects patient responses to various therapies. He then discusses the impact of venetoclax and FLT3 inhibitors on patient survival and emphasizes the importance of considering both mutations when assessing prognosis. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
